What do systematic reviews say?

Oral NSAIDs vs placebo or no treatment

• Pain relief for outpatient hysteroscopy 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 340 participants
  Low

Oral NSAIDs vs placebo or no treatment

• Pain relief for outpatient hysteroscopy 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 321 participants
  Low

Oral NSAIDs vs placebo or no treatment

It is very uncertain whether oral NSAID changes vasovagal reaction compared with placebo or no treatment (very low certainty).

• Pain relief for outpatient hysteroscopy 2017 · Cochrane Headline outcomes only
  OR 0.76 [0.2, 2.94]
  1 study · 181 participants
  Very low

Metformin vs placebo co‐treatment

Metformin may leads to higher live birth rate (per woman) compared with placebo co‐treatment (low certainty).

• Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination… 2017 · Cochrane Headline outcomes only
  OR 2.31 [1.24, 4.33]
  2 studies · 180 participants
  Low

Metformin vs placebo co‐treatment

Metformin showed no clear difference in multiple pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).

• Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination… 2017 · Cochrane Headline outcomes only
  OR 0.55 [0.15, 1.95]
  4 studies · 232 participants
  Low

Metformin vs placebo co‐treatment

Metformin may leads to higher ongoing pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).

• Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination… 2017 · Cochrane Headline outcomes only
  OR 2.46 [1.36, 4.46]
  4 studies · 232 participants
  Low

Metformin vs placebo co‐treatment

Metformin may leads to higher clinical pregnancy rate (per woman) compared with placebo co‐treatment (low certainty).

• Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination… 2017 · Cochrane Headline outcomes only
  OR 2.51 [1.46, 4.31]
  5 studies · 264 participants
  Low

Mifepristone (all doses) vs placebo

Mifepristone probably leads to lower prevalence of dysmenorrhoea compared with placebo (moderate certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.08 [0.04, 0.17]
  1 study · 352 participants
  Moderate

Mifepristone (all doses) vs placebo

Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 0.23 [0.1, 0.51]
  1 study · 223 participants
  Low

Mifepristone (all doses) vs placebo

Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 686.16 [92.29, 5101.33]
  1 study · 360 participants
  High

Mifepristone (all doses) vs placebo

Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).

• Progesterone receptor modulators for endometriosis 2017 · Cochrane Headline outcomes only
  OR 28.79 [3.93, 210.73]
  1 study · 360 participants
  High

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 158 participants
  Very low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  RR 0.64 [0.26, 1.58]
  3 studies · 196 participants
  Very low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  206 participants
  Very low

Oestrogen vs placebo

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Oestrogen vs placebo

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Oestrogen vs placebo

• Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 171 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 200 participants
  Moderate

SPRM vs placebo

• Selective progesterone receptor modulators (SPRMs) for uterine fibroids 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 310 participants
  Moderate